Literature DB >> 19589485

Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.

Junya Kanda1, Chisaki Mizumoto, Hiroshi Kawabata, Tatsuo Ichinohe, Hideyuki Tsuchida, Naohisa Tomosugi, Keitaro Matsuo, Kouhei Yamashita, Tadakazu Kondo, Takayuki Ishikawa, Takashi Uchiyama.   

Abstract

The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early infectious complications after allogeneic HSCT. We studied 55 consecutive adult patients with a median age of 47 years (range: 20-64 years) who underwent allogeneic HSCT for hematologic malignancies at our institution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies. The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4-371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3-37 ng/mL]; n = 17). When cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were compared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was significantly higher in the high-hepcidin group (> or = 50 ng/mL; n = 17) than in the low-hepcidin group (<50 ng/mL; n = 38) (65% [95% confidence interval, 38%-82%] versus 11% [3%-23%]; P < .001). This finding was confirmed by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein (CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589485     DOI: 10.1016/j.bbmt.2009.04.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  Serum hepcidin following autologous hematopoietic cell transplantation: an illustration of the interplay of iron status, erythropoiesis and inflammation.

Authors:  Aurélie Jaspers; Frédéric Baron; Evelyne Willems; Laurence Seidel; Erwin T Wiegerinck; Dorine W Swinkels; Yves Beguin
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

2.  Iron-related markers are associated with infection after liver transplantation.

Authors:  Jennifer K L Chow; Tomas Ganz; Robin Ruthazer; Mary Ann Simpson; Elizabeth A Pomfret; Fredric D Gordon; Mark E Westerman; David R Snydman
Journal:  Liver Transpl       Date:  2017-12       Impact factor: 5.799

3.  Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.

Authors:  Takayuki Sato; Tatsuo Ichinohe; Junya Kanda; Kouhei Yamashita; Tadakazu Kondo; Takayuki Ishikawa; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2011-04-05       Impact factor: 2.490

4.  Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?

Authors:  Ann-Kathrin Eisfeld; Mark Westerman; Rainer Krahl; Sabine Leiblein; Uwe Gerd Liebert; Marianne Hehme; Daniel Teupser; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Adv Hematol       Date:  2011-05-05

5.  High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.

Authors:  Soichiro Sakamoto; Hiroshi Kawabata; Junya Kanda; Tatsuki Uchiyama; Chisaki Mizumoto; Toshiyuki Kitano; Tadakazu Kondo; Masakatsu Hishizawa; Naohisa Tomosugi; Akifumi Takaori-Kondo
Journal:  Cancer Med       Date:  2016-12-01       Impact factor: 4.452

Review 6.  The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Authors:  Sarah Weber; Anastasia Parmon; Nina Kurrle; Frank Schnütgen; Hubert Serve
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

Review 7.  Hepcidin in Children and Adults with Acute Leukemia or Undergoing Hematopoietic Cell Transplantation: A Systematic Review.

Authors:  Artur Słomka; Monika Łęcka; Jan Styczyński
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

8.  Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.

Authors:  Michelle Pirotte; Marianne Fillet; Laurence Seidel; Aurélie Jaspers; Fréderic Baron; Yves Beguin
Journal:  Am J Hematol       Date:  2021-08-24       Impact factor: 13.265

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.